{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:39Z","timestamp":1791727779012,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Zambon Biotech SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00898-z","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:53:31Z","timestamp":1771779211000},"page":"829-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing the Treatment of Motor Fluctuations in Parkinson\u2019s Disease with a Next-Generation Levodopa\/Carbidopa Formulation"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-0033","authenticated-orcid":false,"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Knecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Wach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-3326","authenticated-orcid":false,"given":"Jaakko","family":"Kopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-1431","authenticated-orcid":false,"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"issue":"23","key":"898_CR1","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"PA Lewitt","year":"2008","unstructured":"Lewitt PA. Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med. 2008;359(23):2468\u201376.","journal-title":"N Engl J Med"},{"issue":"6","key":"898_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, et al. Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm. 2025;132(6):743\u201379.","journal-title":"J Neural Transm"},{"issue":"6","key":"898_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archneur.62.6.905","volume":"62","author":"F Stocchi","year":"2005","unstructured":"Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62(6):905\u201310.","journal-title":"Arch Neurol"},{"issue":"1","key":"898_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E","volume":"15","author":"LV Metman","year":"2000","unstructured":"Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson\u2019s disease: hypotheses on the why, where, and what. Mov Disord. 2000;15(1):3\u20138.","journal-title":"Mov Disord"},{"issue":"7","key":"898_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol. 2006;2(7):382\u201392.","journal-title":"Nat Clin Pract Neurol"},{"issue":"1","key":"898_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WNF.0000000000000314","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharmacol. 2019;42(1):4\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"898_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mds.29685","volume":"39","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Hauser RA, Dhall R, et al. Safety and efficacy of IPX203 in Parkinson\u2019s disease: the RISE-PD open-label extension study. Mov Disord. 2024;39(2):428\u201332.","journal-title":"Mov Disord"},{"issue":"10","key":"898_CR8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 2023;80(10):1062\u20139.","journal-title":"JAMA Neurol"},{"issue":"S4","key":"898_CR9","doi-asserted-by":"publisher","first-page":"iv43","DOI":"10.1007\/s00415-005-4009-4","volume":"252","author":"F Stocchi","year":"2005","unstructured":"Stocchi F. Optimising levodopa therapy for the management of Parkinson\u2019s disease. J Neurol. 2005;252(S4):iv43\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"898_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80\u20139.","journal-title":"Mov Disord"},{"key":"898_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: what have we learned over 40\u00a0years? Parkinsonism Relat Disord. 2018;51:9\u201316.","journal-title":"Parkinsonism Relat Disord"},{"key":"898_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251352416","author":"B Heim","year":"2025","unstructured":"Heim B, Poewe W. Unmet needs in the pharmacological management of motor symptoms in Parkinson\u2019s disease. J Parkinsons Dis. 2025. https:\/\/doi.org\/10.1177\/1877718X251352416.","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"898_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology\/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson\u2019s Disease: I. invasive therapies. Mov Disord. 2022;37(7):1360\u201374.","journal-title":"Mov Disord"},{"issue":"11","key":"898_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret M, Weiss D, Stocchi F, V\u00e9rin M, Jost WH. Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm. 2023;130(11):1411\u201332.","journal-title":"J Neural Transm"},{"issue":"2","key":"898_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ncl.2024.12.010","volume":"43","author":"L Marsili","year":"2025","unstructured":"Marsili L, Bologna M, Chen LY, Espay AJ. Treatment of motor symptoms of Parkinson\u2019s disease. Neurol Clin. 2025;43(2):341\u201363.","journal-title":"Neurol Clin"},{"issue":"11 Suppl 2","key":"898_CR16","first-page":"20","volume":"39","author":"RE Dempski","year":"1989","unstructured":"Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology. 1989;39(11 Suppl 2):20\u20134.","journal-title":"Neurology"},{"issue":"4","key":"898_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00002826-199108000-00003","volume":"14","author":"IR Wilding","year":"1991","unstructured":"Wilding IR, Hardy JG, Davis SS, et al. Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol. 1991;14(4):305\u201321.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"898_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0025-6196(12)62690-1","volume":"63","author":"JE Ahlskog","year":"1988","unstructured":"Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson\u2019s disease. Mayo Clin Proc. 1988;63(9):876\u201386.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"898_CR19","first-page":"54","volume":"27","author":"MH Marion","year":"1987","unstructured":"Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson\u2019s disease. Eur Neurol. 1987;27(Suppl 1):54\u20138.","journal-title":"Eur Neurol"},{"issue":"9","key":"898_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-017-0511-y","volume":"56","author":"A Mittur","year":"2017","unstructured":"Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary\u00ae, an extended-release capsule formulation of carbidopa\u2013levodopa. Clin Pharmacokinet. 2017;56(9):999\u20131014.","journal-title":"Clin Pharmacokinet"},{"issue":"7 Suppl 6","key":"898_CR21","first-page":"S23","volume":"44","author":"WC Koller","year":"1994","unstructured":"Koller WC, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1994;44(7 Suppl 6):S23\u20138.","journal-title":"Neurology"},{"issue":"4","key":"898_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.43.4.677","volume":"43","author":"R Pahwa","year":"1993","unstructured":"Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa\/levodopa in Parkinson\u2019s disease. Neurology. 1993;43(4):677\u201381.","journal-title":"Neurology"},{"issue":"11 Suppl 2","key":"898_CR23","first-page":"25","volume":"39","author":"KC Yeh","year":"1989","unstructured":"Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39(11 Suppl 2):25\u201338.","journal-title":"Neurology"},{"issue":"9","key":"898_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/mds.22587","volume":"24","author":"PA LeWitt","year":"2009","unstructured":"LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord. 2009;24(9):1319\u201324.","journal-title":"Mov Disord"},{"issue":"5","key":"898_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA De Bie","year":"2025","unstructured":"De Bie RMA, Katzenschlager R, Swinnen BEKS, et al. Update on treatments for Parkinson\u2019s disease motor fluctuations\u2014an International Parkinson and Movement Disorder Society evidence-based medicine review. Mov Disord. 2025;40(5):776\u201394.","journal-title":"Mov Disord"},{"key":"898_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2023.100197","volume":"8","author":"P LeWitt","year":"2023","unstructured":"LeWitt P, Ellenbogen A, Burdick D, et al. Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation. Clin Parkinsonism Relat Disord. 2023;8:100197.","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"4","key":"898_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase\u00a03 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346\u201356.","journal-title":"Lancet Neurol"},{"key":"898_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.parkreldis.2020.12.002","volume":"82","author":"RA Hauser","year":"2021","unstructured":"Hauser RA, Zeitlin L, Fisher S, D\u2019Souza R. Duration of benefit per dose: carbidopa-levodopa immediate release vs. extended release capsules (Rytary\u00ae). Parkinsonism Relat Disord. 2021;82:133\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"898_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/08971900221151194","volume":"37","author":"C Livingston","year":"2024","unstructured":"Livingston C, Monroe-Duprey L. A review of levodopa formulations for the treatment of Parkinson\u2019s disease available in the United States. J Pharm Pract. 2024;37(2):485\u201394.","journal-title":"J Pharm Pract"},{"issue":"5","key":"898_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/WNF.0000000000000354","volume":"42","author":"NB Modi","year":"2019","unstructured":"Modi NB, Mittur A, Dinh P, Rubens R, Gupta S. Pharmacodynamics, efficacy, and safety of IPX203 in Parkinson disease patients with motor fluctuations. Clin Neuropharmacol. 2019;42(5):149\u201356.","journal-title":"Clin Neuropharmacol"},{"issue":"S2","key":"898_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257(S2):253\u201361.","journal-title":"J Neurol"},{"issue":"5","key":"898_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/JPD-230372","volume":"14","author":"A Demailly","year":"2024","unstructured":"Demailly A, Moreau C, Devos D. Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: a review of L-DOPA pharmacokinetics\/pharmacodynamics. J Parkinsons Dis. 2024;14(5):925\u201339.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"898_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat Commun. 2019;10(1):310.","journal-title":"Nat Commun"},{"issue":"1","key":"898_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","volume":"8","author":"M Beckers","year":"2022","unstructured":"Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease. npj Parkinson\u2019s Dis. 2022;8(1):56.","journal-title":"npj Parkinson's Dis"},{"key":"898_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100357","volume":"13","author":"RA Hauser","year":"2025","unstructured":"Hauser RA, Torres-Yaghi Y, Fisher S, Banisadr G. How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT\u00ae) in patients with Parkinson\u2019s disease. Clin Parkinsonism Relat Disord. 2025;13:100357.","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"8","key":"898_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74(8):1071\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"898_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2125.2002.01654.x","volume":"54","author":"H Heikkinen","year":"2002","unstructured":"Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa\/carbidopa dose. Br J Clin Pharmacol. 2002;54(4):363\u201371.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"898_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1212\/WNL.44.5.913","volume":"44","author":"JG Nutt","year":"1994","unstructured":"Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44(5):913\u20139.","journal-title":"Neurology"},{"issue":"11","key":"898_CR39","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O, et al. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson\u2019s disease. Mov Disord. 2022;37(11):2272\u201383.","journal-title":"Mov Disord"},{"issue":"1 Suppl 1","key":"898_CR40","first-page":"S64","volume":"62","author":"RA Hauser","year":"2004","unstructured":"Hauser RA. Levodopa\/carbidopa\/entacapone (Stalevo). Neurology. 2004;62(1 Suppl 1):S64-71.","journal-title":"Neurology"},{"issue":"12","key":"898_CR41","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa\u2013levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20(12):1335\u201340.","journal-title":"Parkinsonism Relat Disord"},{"key":"898_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107239","volume":"131","author":"RA Hauser","year":"2025","unstructured":"Hauser RA, Fernandez HH, Jimenez-Shahed J, et al. Duration of \u201cGood On\u201d time per dose: immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT\u00ae). Parkinsonism Relat Disord. 2025;131:107239.","journal-title":"Parkinsonism Relat Disord"},{"key":"898_CR43","unstructured":"Hauser RA, Moore HP, Banisadr G, D\u2019Souza R. Optimizing a patient\u2019s oral CD-LD dosing regimen is critical for improving efficacy in Parkinson\u2019s disease. Poster Presented at American Academy of Neurology 2024 Annual Meeting, April 13\u201318, 2024, Denver, Colorado. 2024."},{"issue":"Suppl 1","key":"898_CR44","first-page":"688","volume":"39","author":"S Isaacson","year":"2024","unstructured":"Isaacson S, Fernandez H, Kilbane C, et al. Impact of IPX203 on Parkinson\u2019s patients\u2019 motor states upon awakening: analysis of patient diary data [MDS abstract 688]. Mov Disord. 2024;39(Suppl 1):688.","journal-title":"Mov Disord"},{"issue":"5","key":"898_CR45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","volume":"19","author":"RMA De Bie","year":"2020","unstructured":"De Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson\u2019s disease: when, why, and how. Lancet Neurol. 2020;19(5):452\u201361.","journal-title":"Lancet Neurol"},{"issue":"10","key":"898_CR46","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/mdc3.14198","volume":"11","author":"LG Ramanzini","year":"2024","unstructured":"Ramanzini LG, Frare JM, Camargo LFM, Silveira JOF, Jankovic J. Does delaying levodopa prevent motor complications in Parkinson\u2019s disease? A meta-analysis. Mov Disord Clin Pract. 2024;11(10):1195\u2013202.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"898_CR47","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/WCO.0000000000000113","volume":"27","author":"R Pahwa","year":"2014","unstructured":"Pahwa R, Lyons KE. Treatment of early Parkinson\u2019s disease. Curr Opin Neurol. 2014;27(4):442\u20139.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"898_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","volume":"23","author":"A Lees","year":"2023","unstructured":"Lees A, Tolosa E, Stocchi F, et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother. 2023;23(1):15\u201324.","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"898_CR49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol. 2024;20(12):695\u2013707.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"898_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.2025.003","volume":"48","author":"N Mouchaileh","year":"2025","unstructured":"Mouchaileh N, Cameron J. Device-assisted therapies for Parkinson disease. Aust Prescr. 2025;48(1):10\u20137.","journal-title":"Aust Prescr"},{"issue":"Suppl","key":"898_CR51","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2007.06.005","volume":"13","author":"D Nyholm","year":"2007","unstructured":"Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S13\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"898_CR52","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-202104","volume":"10","author":"JM Dijk","year":"2020","unstructured":"Dijk JM, Espay AJ, Katzenschlager R, De Bie RMA. The choice between advanced therapies for Parkinson\u2019s disease patients: why, what, and when? J Parkinsons Dis. 2020;10(s1):S65\u201373.","journal-title":"J Parkinsons Dis"},{"key":"898_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.parkreldis.2020.10.042","volume":"83","author":"L Marsili","year":"2021","unstructured":"Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson\u2019s disease advanced therapies\u2014a systematic review: more unanswered questions than guidance. Parkinsonism Relat Disord. 2021;83:132\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"898_CR54","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3233\/JPD-202348","volume":"11","author":"K Smilowska","year":"2021","unstructured":"Smilowska K, Van Wamelen DJ, Pietrzykowski T, et al. Cost-effectiveness of device-aided therapies in Parkinson\u2019s disease: a structured review. J Parkinsons Dis. 2021;11(2):475\u201389.","journal-title":"J Parkinsons Dis"},{"key":"898_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord. 2021;92:59\u201366.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"898_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-025-00383-2","volume":"7","author":"M Sudmeyer","year":"2025","unstructured":"Sudmeyer M, Pedrosa DJ, Siebecker F, Arlt C, Kopra J, Jost WH. Real-world disease burden and planned treatment optimization after MANAGE-PD implementation in Germany: a cross-sectional study. Neurol Res Pract. 2025;7(1):31.","journal-title":"Neurol Res Pract"},{"issue":"7","key":"898_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14070630","volume":"14","author":"M S\u00fcdmeyer","year":"2024","unstructured":"S\u00fcdmeyer M, Pedrosa DJ, Siebecker F, Arlt C, Kopra JJ, Jost WH. Utilization of MANAGE-PD tool in a real-world setting in Germany: a cross-sectional study. Brain Sci. 2024;14(7):630.","journal-title":"Brain Sci"},{"key":"898_CR58","unstructured":"H\u00f6glinger G, Trenkwalder C. Parkinson-Krankheit, S2k-Leitlinie, 2023. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00898-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00898-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:08:12Z","timestamp":1778684892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00898-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00898-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabrizio Stocchi has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Synegile, Biogen, Roche, Blue Rock, Chiesi Pharmaceuticals, Lundbeck, Sunovion and Kiowa. Jaime Kulisevsky during the last 24\u00a0months has received honoraria for consulting and\/or lecturing from: Abbvie, Zambon, Prilenia, Bial, Stada, Britannia, General Electric, SOM-Biotech, MediBiopharma, UCB and Ferrer. Mathias Knecht and Jaakko Kopra are employees, while Ivan Marjanovic and Achim Wach are consultants of Zambon Biotech SA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}